Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
PDBC vs XBI: how they differ
PDBC and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, PDBC and XBI hold 0% of their money in the same securities at the same weight.
| Only in PDBC | Only in XBI |
|---|---|
| Invesco Premier US Government Money Port 75.58% | MODERNA INC 2.87% |
| POWERSHARES CAYMAN FUND 24.42% | TWIST BIOSCIENCE CORP 1.81% |
| HALOZYME THERAPEUTICS INC 1.47% | |
| NATERA INC 1.46% | |
| KYMERA THERAPEUTICS INC 1.45% | |
| TRAVERE THERAPEUTICS INC 1.40% | |
| ROIVANT SCIENCES LTD 1.39% | |
| ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| PDBC Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Invesco | State Street |
| What it is | Optimum Yield Diversified Commodity Strategy | SPDR S&P Biotech |
| Total return, 1 year | +55.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +37.7 pts | +46.5 pts |
| Expense ratio | 0.59% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 2 | 154 |
PDBC in plain words
PDBC is an index equity fund tracking the Optimum Yield Diversified Commodity Strategy. Over the year to Sep 11, 2026 it returned +55.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.59% a year. By its holdings filed for Sep 10, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 2 positions, with the top ten at 100.0%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, PDBC or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, PDBC returned +55.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, PDBC or XBI?
- PDBC charges 0.59% a year and XBI charges 0.35%, so XBI is cheaper. Fees come from each fund's prospectus.
- How much do PDBC and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of PDBC and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, PDBC against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/pdbc-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources